Real-World Insights in Cancer

REAL-WORLD EVIDENCE SOLUTIONS

MEET THE FUTURE OF REAL-WORLD INSIGHTS IN CANCER

An RWE ecosystem for commercial and clinical success

CHALLENGES

Cancer and its Complexity Discovering and assessing cancer therapies demands the best insights into disease etiology, treatment, impact, and outcomes. Robust analyses must account for the specific interests of all stakeholders and a variety of issues across the spectrum of cancers.

• Clinicians facing highly sophisticated

treatment decisions and patient stratification • Payers wanting more proof of value as innovations challenge stretched budgets • Pharma generating more innovative evidence

2

• Patients and caregivers impacting

therapeutic options • Increasing role of advocacy groups in awareness building and data generation

HOLISTIC APPROACH

IMS RWE Cancer Ecosystem IMS Health combines anonymous patient data with advanced analytics, powerful processing, and deep scientific and commercial expertise to deliver credible, breakthrough oncology insights.

Creating a common foundation of the right oncology real-world data (RWD) to address the cancer-related needs of your entire organization

www.imshealth.com/rwe

3

IMS RWE CANCER ECOSYSTEM

Unparalleled Oncology Capabilities

Expertise-Driven Oncology Services Delivered by a global, dedicated team, including tumor-specific specialists

Technology-Enabled Analytics Innovative and client-centric technology solutions

Comprehensive, Global Cancer Data Multi-source data representing macro-to-patient-level RWD

4

• Disease, patient, and therapy

• Real-world value demonstration,

• Largest, most comprehensive

• Intelligent data interfaces and

• Comprehensive cross-sectional

• More than 10 years of data from

understanding • R&D targeting and efficiency • Market access strategies

cancer platform commercially available in the USA • EMR extraction capabilities in Europe • Predictive analytics algorithms

survey data

-C overage of 25+ primary cancers across 15+ markets

- 200,000+ patient histories per year from 4,000+ specialists • IMS MIDAS sales data integration • Primary data collection from specialists and patients • Promotional data

www.imshealth.com/rwe

including HEOR, pharmacoepidemiology, and drug safety • Commercial positioning, planning, and performance tracking

visualization • Data-linking technologies designed to protect privacy

15+ million anonymous cancer patients -E MR data - Medical claims data - Hospital data - Prescription data - Consumer data - Biomarker and genomic alteration data

5

UNIQUE APPROACH TO DATA

Partnering for Richer Data to Support Precision Therapy The IMS Health and Foundation Medicine collaboration enables unique linkage of biomarker data with other sources of RWD such as payer claims and oncology EMR at an anonymous patient level. This provides an unprecedented evidence base for improved medical-scientific and commercialization strategies.

• Granular understanding of the

comprehensive patient pathway • Insights into differences in unmet needs, treatment use, cost, and outcomes among different genomic subpopulations • Evaluation of targeted therapies, based on unique molecular drivers of individual cancers

Biomarker Duration of Therapy Median Days on Erlotinib Therapy (linked cohort n=152) 365 358 312

135

EGFR-

115

107

EGFR+

EGFR+ Exon 20 mut

EGFR+ non-Exon 20 mut

KRAS+

KRAS-

Source: IMS Health retrospective analysis of IMS RWD Pharmacy Prescription and Medical Claims linked to Foundation Medicine molecular profiling data

6

CUSTOM RWD SOLUTIONS

Sourcing and Linking Expertise for T-Shaped Evidence Networks Strategic Data Sourcing sourcing support to extract data and create custom datasets • Identify and access new data sources addressing specific research needs, also in niche markets • Benefit from IMS RWD Catalogue of 2,200+ data sources globally, including 40%+ in oncology

T-Shaped Evidence Networks Broad

Nationally relevant databases Augmented datasets Range of Data Types

• Enhance existing RWD through custom

Biobank, labs, registries

Data Linkage

• Understand the full patient pathway

through integrating datasets at the record level (e.g., USA and Scandinavia) • Gain deeper insights by sales indication through integration with IMS MIDAS sales data

www.imshealth.com/rwe

Deep Population Coverage

IMS Health T-shaped Evidence Networks address the need to consider both breadth and depth of RWD when accessing the most appropriate fact base

7

 OUR SCIENTIFIC COMMITMENT

Bringing Scientific Credibility and Quality to All Our Work IMS Health has established excellence in global and local cancer-related research in mature and emerging markets.

Proven Approach: We have a track record of successful HTA submissions, published findings, and EMA-accepted Drug Utilization Studies in multiple therapy areas and geographies. Our bibliography comprises more than 3,500 publications, with 520+ in solid and liquid tumors. redible Solutions: Our databases and methods have been C validated in peer-reviewed publications and are used by academics and authorities. They serve as part of a framework for safety assessment and for regulatory purposes.

Quality Systems: Our leading Quality Management System includes electronic control of standards, audit trail, and computer system validation.

8

SERVICES

Helping Stakeholders All functions can derive value through a shared view of what is happening in real-life healthcare settings.

R&D

• Translational research • Drug pathways • Target population/product profile • Trial and recruitment feasibility

HEOR, Pharmacoepidemiology, and Drug Safety

• Drug utilization/monitoring • Rigorous and efficient tumor modeling • EMR-enabled outcomes research • Local burden of illness/disease • Adverse event/signal detection • Regulatory submissions and responses

Commercial

• Launch pricing support • Tumor-specific forecasting • Ongoing value differentiation • Launch/promotion planning • Segmentation and targeting • Cancer patient journeys www.imshealth.com/rwe

RWE Platform Developers

• Custom data sourcing • E360TM technology suite • Evidence platforms • T-shaped Cancer Evidence Networks 9

EVIDENCE PLATFORM

IMS RWD Oncology US Platform Our comprehensive cancer data platform links multiple data types, including EMRs, across settings of care.

• More than 10 years

• Geographically

of data from 15+ million anonymous cancer patients

Services & Engagement

representative of the USA to enable a projectable base

• Integrates biomarker, histology, consumer, and other patient datasets

R&D

Medical-Scientific

HEOR

Commercial

Predictive Analytics Tools

Studies/ Publications

Forecasting & KOL Engagement

Patient Analytics

Software Application (e.g., E360TM, SAS, R, Tableau)

Platform Core

TechnologyEnabled Analytics

• Data Integration • Data Hosting • Business Rules & Analytical Methods • Ongoing Data Governance

Broad, Nationally Relevant Databases (e.g., IMS RWD Claims Data) Augmented Datasets (e.g., Oncology EMR)

Real-World Data

10

T-Shaped Portfolio of Data Sources

Deep Clinical Data (e.g., Genomics Data)

Enriched Data (e.g., NLP, Linkage, Local Registry)

HOW WE HELP

Enhancing RCT Results with RWE OUR CHALLENGE Help our client determine whether the rate and timing of hemoglobin (Hb) decline in cancer patients receiving chemotherapy seen in pooled RCT was representative of the real world.

440 Patients

OUR SOLUTION We analyzed pooled data from six RCTs and replicated the analysis using our US community oncology clinic EMR database.

5,922

Additional patient experiences analyzed

OUR RESULTS Our analysis verified the RCT findings, increasing payer confidence in those clinical results. This approach can help support future launch strategies when there is uncertainty regarding the applicability of RCT results to real-life settings.

www.imshealth.com/rwe

11

NEW IN 2016!

IMS RWD Oncology Dynamics

The latest addition to the IMS Health cross-sectional survey portfolio • Facilitates • New global study covering all key tumor understanding of types, stages, and lines cancer treatment paradigms of therapy • Large physician panel • Modern, web-based analytical tool to gain with high patient immediate insights sample sizes https://websolutions.imshealth.com/EB2/User/CustomerLogin

IMS RWD Oncology Dynamics

Patient Profile Key Cancer: Patient Count

NSCLC: Line of Therapy

KEY CANCER

CONTACT US FOR MORE INFORMATION The Americas One IMS Drive Plymouth Meeting, PA 19462 USA Tel: +1 484 567 6461 Europe 210 Pentonville Road London, N1 9JY United Kingdom Tel: +44 (0) 20 3075 4800 rweinfo@imshealth.com www.imshealth.com/rwe www.linkedin.com/company/ ims-health-real-world-evidence www.twitter.com/IMSHealthRWE

1st

NSCLC COLORECTAL BREAST ALL OTHERS PROSTATE NHL PANCREAS KIDNEY OVARIAN CLL BLADDER CML STOMACH SCLC AML MELANOMA

3rd+

2nd ALK Status NSCLC

Not Tested 0

100

200

Count (Patient-ID)

Awaiting Results

IMS HEALTH REAL-WORLD EVIDENCE SOLUTIONS

Wild

300 Mutant

IMS Health Real-World Evidence Solutions Uncovering insights from real-world data to improve decision making and patient outcomes ©2016 IMS Health Incorporated and its affiliates. All rights reserved.

IMS HEALTH, IMS HEALTH INTELLIGENCE APPLIED and E360 are trademarks of IMS Health Incorporated.